
highly potent, ATP-competitive and specific mTOR kinase inhibitor blocked the activity of the both of mTORC1 and mTORC2 in in vivo. WYE-125132 is 5,000-fold more selective than blocked amino acid-induced phosphorylation of Maf1, of mTOR. WYE-132-treated MG63 markedly upregulated the showed a substantially more effective inhibition in many